1,080 material Form 8-K filings that 839 companies we cover made with the SEC in May 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Oyster Enterprises II Acquisition Corp, a blank check company, closed its upsized initial public offering on May 23, 2025, selling 25,300,000 units at $10.00 per unit for gross proceeds of $253,000,000. The full $253,000,000 was placed in a U.S. trust account, and funds generally stay there until an initial business combination is completed or public shares are redeemed if none is completed within 24 months of the IPO closing.
25,300,000 units sold at $10.00 each, including 3,300,000 units from the full exercise of the underwriters' over-allotment option; units began trading on Nasdaq as OYSEU on May 22, 2025.
$253,000,000 placed in a trust account maintained by Continental Stock Transfer & Trust Company; trust funds are not released until a business combination or redemption within 24 months.
Private placement of 708,000 units to the Sponsor and BTIG at $10.00 per unit, for an aggregate purchase price of $7,080,000.
Divya K. Narendra, Lief Haniford and Jordan Fliegel appointed to the board effective May 21, 2025; Mr. Narendra chairs the Audit Committee and Mr. Haniford chairs the Compensation Committee.
ProCap Acquisition Corp closed its upsized initial public offering on May 22, 2025, selling 25,000,000 units at $10.00 each for gross proceeds of $250,000,000, including 3,000,000 units from a partial exercise of the underwriters' over-allotment option. As a blank check company, it has not yet identified a business combination, and $247,725,000 of the proceeds is held in a trust account that is not released until a business combination or redemption occurs, which matters to shareholders because their capital stays restricted in trust until then.
IPO closed May 22, 2025: 25,000,000 units at $10.00 per unit, gross proceeds of $250,000,000, with 3,000,000 units from partial over-allotment exercise
$247,725,000 placed in a U.S.-based trust account with Odyssey Transfer and Trust Company, as trustee
Sponsor bought 430,000 private placement units at $10.00 each, for gross proceeds of $4,300,000
Lindsey Haswell, Michael Gonzalez and Benjamin Buchanan appointed directors on May 20, 2025; Buchanan chairs the audit and compensation committees
Three directors, Timothy P. Boyle, Hon. Dave McCurdy and Kenneth Thrasher, left the Northwest Natural Holding board at the May 22, 2025 annual meeting, and the board reduced its size from 13 to 10 members. Shareholders elected five directors, approved an amended Long Term Incentive Plan that raises authorized shares to 2,250,000, approved the advisory pay vote, and ratified PricewaterhouseCoopers as auditor for 2025.
Boyle, McCurdy and Thrasher departed the holding company board effective May 22, 2025; Steven E. Wynne also retired from the NW Natural subsidiary board.
Board size reduced from 13 to 10 members; retirements followed the length-of-service guidelines in the company's governance documents.
Incentive plan approved with 28,478,915 for, 2,004,285 against and 140,094 abstaining; authorized shares raised to 2,250,000.
Say-on-pay approved with 29,310,087 for and 1,146,255 against; PricewaterhouseCoopers ratified with 33,733,113 for.
Wen Acquisition Corp, a blank check company, closed its initial public offering on May 19, 2025, selling 30,015,000 units at $10.00 per unit for $300.15 million, including units from the full exercise of the underwriters' over-allotment option. The $300.15 million was placed in a U.S.-based trust account, and the company has not yet selected a business combination target. Shareholders' public shares are redeemable from the trust if the company does not complete a business combination within 24 months of the IPO closing.
IPO closed May 19, 2025: 30,015,000 units at $10.00 each, including 3,915,000 units from the full over-allotment exercise.
Each unit includes one Class A ordinary share and one-half of one redeemable warrant exercisable at $11.50 per share.
Private placement of 7,220,000 warrants at $1.00 each raised $7.22 million; sponsor Wen Sponsor LLC bought 4,610,000 and Cantor Fitzgerald & Co. bought 2,610,000.
Balance sheet as of May 19, 2025 shows cash of $1,239,820 and $300,150,000 held in the Trust Account, with Continental Stock Transfer & Trust Company as trustee.
At its May 23, 2025 annual meeting, Pebblebrook Hotel Trust shareholders approved an amendment to the 2009 Equity Incentive Plan. The amendment adds 3,000,000 common shares to the plan and extends the period for granting awards to June 30, 2036. Shareholders also elected seven trustees, ratified KPMG LLP as auditor, and approved executive pay in an advisory vote.
Plan amendment adds 3,000,000 common shares for equity awards, effective May 23, 2025
Award-granting period under the plan extended to June 30, 2036
Plan amendment approved with 104,409,145 votes for and 5,333,851 against
Say-on-pay advisory vote approved with 101,922,811 votes for and 7,819,667 against
Mirion Technologies completed a private offering of $400.0 million of 0.25% convertible senior notes due June 1, 2030, on May 23, 2025, after increasing the deal from $300.0 million and exercising in full the initial purchasers' $50.0 million option. The company will use net proceeds of approximately $387.7 million to pay for capped call transactions, repay $250.0 million of its senior secured term loan, and repurchase $31.0 million of Class A common stock.
Notes total $400.0 million principal, mature June 1, 2030, and pay 0.25% annual interest semiannually starting December 1, 2025
Initial conversion price is approximately $23.11 per share, a 32.5% premium to the May 20, 2025 NYSE closing price
Net proceeds of approximately $387.7 million fund a $44.6 million capped call cost, a $250.0 million term loan repayment, and a $31.0 million share repurchase
Company may not redeem the notes before June 6, 2028, and holders can require repurchase at par plus accrued interest upon a fundamental change
Hyatt's board cut from thirteen to eleven members after director Michael Rocca did not stand for re-election and James Wooten retired, neither citing a disagreement with the company. At the May 21, 2025 annual meeting, shareholders re-elected four Class I directors, ratified Deloitte & Touche as auditor, and rejected a proposal to eliminate the multi-class share structure.
Board size reduced from 13 to 11 members; Wooten's retirement took effect May 22, 2025
Stockholder proposal to eliminate multi-class share structure received 28,162,808 FOR votes versus 540,861,841 AGAINST
Deloitte & Touche LLP ratified as independent auditor for fiscal 2025 with 572,702,051 FOR votes
Tracey T. Travis appointed to the Audit Committee effective May 22, 2025
DaVita completed a $1.0 billion private offering of 6.750% senior notes due July 15, 2033, with net proceeds of approximately $986 million. The company plans to use $830 million to repay revolving credit facility borrowings, with the remainder for general corporate purposes, including stock repurchases, working capital and capital expenditures.
Offering size: $1.0 billion aggregate principal of 6.750% Senior Notes due 2033, closed May 23, 2025
Approximately $986 million in net proceeds after initial purchasers' discount and fees
$830 million of proceeds earmarked to repay outstanding revolving credit facility borrowings
Notes are unsecured, rank equally with other senior debt, and are not listed on any securities exchange
On May 21, 2025, Tandem Diabetes and Roche entities agreed to settle all patent disputes over the t:slim X2 pump, terminating pending actions before Unified Patent Court divisions in France and Germany. The Tandem entities will pay $36 million over five years, starting with an $8 million initial payment, and the parties granted each other 10-year licenses to insulin delivery patents. The same day, shareholders elected all eight directors, approved executive pay on an advisory basis, and ratified Ernst & Young as auditor.
Settlement resolves disputes over the t:slim X2 pump and two Roche-related EP patents, ending pending actions in France and Germany.
Tandem entities will pay $36 million over five years: an $8 million initial payment, then four equal annual installments.
Cross-licenses of insulin delivery system patents run for 10 years from the May 21, 2025 effective date.
At the May 21, 2025 annual meeting, executive pay was approved with 54,337,934 for and 1,598,126 against, and shareholders chose an annual say-on-pay vote.
Patrick Industries said former CFO Jake Petkovich rejoins the company as President – Marine, effective May 19, 2025, succeeding Rick Reyenger, who moves to a strategic advisory role. The filing discloses Petkovich's employment agreement, including a $500,000 base salary, a 2025 short-term incentive target of $900,000, and equity grants. The change affects leadership of the company's Marine businesses, and the compensation terms are disclosed for shareholders.
Effective May 19, 2025, Jake Petkovich becomes President – Marine, succeeding Rick Reyenger, who stays with the company in a strategic advisory role.
Employment agreement sets an annual base salary of $500,000 and a 2025 short-term incentive target of $900,000.
Equity grants include 10,257 restricted stock units, options on 42,180 shares at $92.72, and 42,180 stock appreciation rights at exercise prices from $92.72 to $158.05.
Petkovich was Patrick's Executive Vice President – Finance, CFO and Treasurer from 2020 to 2023, and CFO of Indicor, LLP from 2023 to the present.
DocuSign entered into a credit agreement on May 21, 2025, providing a $750 million revolving credit facility led by Bank of America, with an option to increase it by $250 million. The company had no outstanding revolving loans under the facility as of May 21, 2025, so the agreement adds borrowing capacity rather than new debt. Shareholders should note the facility is secured by substantially all company assets and includes financial covenants and a change-of-control event of default.
Revolving credit facility of $750 million, expandable by an additional $250 million
Facility matures May 21, 2030; no revolving loans were outstanding as of May 21, 2025
Secured by a first priority interest in substantially all assets of the company and certain subsidiaries
Covenants include a maximum leverage ratio of 3.75:1.00 before an investment grade period
EnerSys said David M. Shaffer retired as CEO and director effective May 22, 2025, and Shawn M. O'Connell became President and CEO and a Class III director effective May 23, 2025. The filing also raises O'Connell's base salary and expands his severance terms, which may matter to shareholders as the company's leadership changes.
Shawn M. O'Connell appointed President and CEO effective May 23, 2025, succeeding David M. Shaffer, who retired effective May 22, 2025.
O'Connell's annual base salary increased to $950,000 and his 2026 incentive payout percentage increased to 115% of base salary.
O'Connell's severance agreement was amended to a lump sum of two times his base compensation plus target annual bonus, with COBRA reimbursement extended to two years.
Andrea J. Funk, CFO, received restricted stock units with a fair market value of $1.5 million on May 23, 2025.
Charles River Laboratories amended CEO James Foster's employment agreement on May 20, 2025, extending his term by one year to February 12, 2027, with all other terms unchanged. At the same meeting, shareholders re-elected seven directors, approved executive pay on an advisory basis, ratified PricewaterhouseCoopers as auditor, and rejected a PETA-submitted proposal on non-human primates.
Foster employment term extended one year to February 12, 2027; other terms unchanged
Seven directors elected to serve until the 2026 Annual Meeting; Steven Barg, Mark Enyedy, Abraham Ceesay and Paul Graves appointed to the Board
Advisory vote on executive compensation: 40,218,870 for and 1,432,240 against
PETA proposal on non-human primates not approved: 3,457,547 for and 38,051,509 against
Agree Limited Partnership, a subsidiary of Agree Realty Corporation, completed an underwritten public offering of $400 million of 5.600% senior unsecured notes due June 15, 2035, guaranteed by the parent. The offering closed May 23, 2025, with net proceeds to the parent guarantor of approximately $393.6 million after the underwriting discount and estimated expenses.
Notes: $400 million principal, 5.600% interest, maturing June 15, 2035; interest paid June 15 and December 15 starting December 15, 2025
Underwriters paid 98.647% of principal for the notes
Net proceeds to the parent guarantor of approximately $393.6 million
Indenture includes limits on additional indebtedness and a requirement to maintain a pool of unencumbered assets
Buckle reported results for the fiscal quarter ended May 3, 2025, with net income of $35.2 million, or $0.70 per diluted share, up from $34.8 million, or $0.69 per diluted share, a year earlier. Net sales rose 3.7% to $272.1 million, and both comparable store sales and online sales increased, which points to higher sales and profit for shareholders in the quarter.
Net sales rose 3.7% to $272.1 million from $262.5 million a year earlier.
Diluted EPS was $0.70 versus $0.69 in the prior-year quarter; net income was $35.2 million versus $34.8 million.
Comparable store net sales increased 3.0%, and online sales rose 4.5% to $46.4 million.
Buckle operated 439 stores in 42 states at quarter end, compared with 440 stores in 42 states a year earlier.
At its May 22, 2025 annual meeting, Lincoln National's shareholders approved Amendment No. 4 to the 2020 Incentive Compensation Plan, adding 1,750,000 shares for a total of 17,800,000 and raising the maximum cash award for non-director participants from $8,000,000 to $12,000,000. The Board also reduced its authorized size from eleven to ten members, and shareholders did not approve a non-binding proposal requiring an independent board chair.
Plan share authorization rose by 1,750,000 shares to 17,800,000, and the cash award cap increased from $8,000,000 to $12,000,000
Bylaws amended effective May 22, 2025 to cut authorized Board seats from eleven to ten
Independent board chair proposal not approved: 44,660,726 for and 71,754,818 against
All ten director nominees elected; Ernst & Young LLP ratified as 2025 auditor with 142,755,514 votes for
At its annual meeting on May 22, 2025, ANI Pharmaceuticals stockholders approved raising authorized common stock from 33,333,334 shares to 66,000,000 shares, effective on filing with the Delaware Secretary of State that day. They also elected eight directors and approved amended 2022 stock incentive and 2016 employee stock purchase plans. The filing does not say how the additional authorized shares will be used, but the increase gives the company room to issue more stock than before.
Authorized common shares increased from 33,333,334 to 66,000,000; the vote was 17,950,106 for and 461,824 against.
All eight director nominees were elected, with Renee P. Tannenbaum receiving the most against votes at 1,368,462.
Amended 2022 Stock Incentive Plan approved with 15,056,885 for and 1,202,893 against.
Advisory say-on-pay proposal approved with 14,565,587 for and 1,689,477 against.
Booz Allen reported fiscal 2025 results for the year ended March 31, 2025, with revenue of $12.0 billion, up 12.4%, and GAAP diluted EPS of $7.25, up from $4.59. The company also projected fiscal 2026 revenue of $12.0 billion to $12.5 billion and adjusted diluted EPS of $6.20 to $6.55, compared with $6.35 in fiscal 2025.
FY2025 revenue was $12.0 billion, up 12.4% year over year; adjusted diluted EPS was $6.35, up 15.5%.
GAAP diluted EPS was $7.25 versus $4.59 a year earlier; net income was $935 million versus $606 million.
FY2026 guidance: revenue of $12.0 billion to $12.5 billion (0% to 4.0% growth) and adjusted diluted EPS of $6.20 to $6.55.
Quarterly dividend of $0.55 per share is payable June 27, 2025, to holders of record on June 11, 2025.
Tapestry entered into a new $2 billion unsecured revolving credit facility dated May 22, 2025, with Bank of America as administrative agent, replacing its existing facility from May 11, 2022. The new facility matures May 22, 2030 and can be increased by up to $750 million, giving the company longer-dated borrowing capacity on terms the filing describes as customary.
New $2 billion unsecured revolving credit facility, maturing May 22, 2030
Replaces the existing credit facility dated May 11, 2022
Commitments may be increased by up to $750 million, subject to conditions
Covenant requires a maximum 4.0 to 1.0 ratio of consolidated debt minus unrestricted cash above $300 million to consolidated EBITDAR
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.